Perpetual LTD Vertex Pharmaceuticals Inc Transaction History

Perpetual LTD

  • $10.2 Trillion
  • Q1 2024

A detailed history of Perpetual LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Perpetual LTD holds 197,351 shares of VRTX stock, worth $87.9 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares
197,351
Previous 197,351 -0.0%
Holding current value
$87.9 Million
Previous $82.5 Billion -0.0%
% of portfolio
0.81%
Previous 0.81%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 09, 2024
SELL
$407.69 - $446.08 $4.22 Million - $4.62 Million
-10,352 Reduced 4.98%
197,351 $82.5 Billion
Q4 2023

Feb 15, 2024
SELL
$343.0 - $410.68 $20.5 Million - $24.6 Million
-59,803 Reduced 22.36%
207,703 $84.5 Billion
Q3 2023

Oct 10, 2023
SELL
$338.18 - $362.46 $1.01 Million - $1.08 Million
-2,976 Reduced 1.1%
267,506 $93 Billion
Q2 2023

Jul 13, 2023
SELL
$314.42 - $351.91 $10.3 Million - $11.5 Million
-32,747 Reduced 10.8%
270,482 $95.2 Billion
Q1 2023

May 08, 2023
BUY
$283.23 - $323.1 $78.8 Million - $89.9 Million
278,379 Added 1120.24%
303,229 $95.5 Billion
Q3 2020

Dec 08, 2020
SELL
$255.65 - $303.1 $483,178 - $572,859
-1,890 Reduced 7.07%
24,850 $6.76 Million
Q2 2020

Nov 18, 2020
SELL
$225.48 - $295.8 $2.29 Million - $3.01 Million
-10,170 Reduced 27.55%
26,740 $16.4 Million
Q1 2020

Nov 18, 2020
BUY
$199.77 - $247.81 $7.37 Million - $9.15 Million
36,910 New
36,910 $23.4 Million

Others Institutions Holding VRTX

# of Institutions
1,625
Shares Held
222M
Call Options Held
1.35M
Put Options Held
1.49M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $114B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Perpetual LTD Portfolio

Follow Perpetual LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perpetual LTD, based on Form 13F filings with the SEC.

News

Stay updated on Perpetual LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email